Immune-related hepatic adverse events in renal cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective study
The combination of ICI with TKI posed higher risks for irHAE in RCC patients. While survival outcomes were unaffected, the results underscore the need for tailored monitoring and management. Prospective studies are warranted to refine therapeutic approaches.
Authors
- Viktor Grünwald (ORCID: https://orcid.org/0000-0003-2083-7687)
- Christopher Darr (ORCID: https://orcid.org/0000-0003-2532-8398)
- Thomas Hilser
- Ayman Saleh (ORCID: https://orcid.org/0000-0003-1126-6018)
Institutions
- Essen University Hospital (DE)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1038/s44276-025-00178-7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitätsklinikum Essen